On October 2010, the Canadian Cardiovascular Society (CCS) issued guidelines specific to the use of antiplatelet therapy, including their use in multiple settings, such as primary and secondary prevention, as well as following PCI and CABG surgery and in patients with peripheral arterial disease and diabetes.

In the US and Europe, guidelines for antiplatelet therapy follow a more disease-based approach.

Join Drs Bob Harrington, Alan Bell, Keith Fox, and Jean-François Tanguay as they discuss the regional differences in the development of guidelines, the reassuring similarities, and the importance of implementation and outcomes measurement.